

**IND SAFETY REPORT: INITIAL WRITTEN REPORT****TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9849**1. IND NUMBER  
**7921**2. AGENT NAME  
**Bevacizumab (rhuMAb VEGF)**3. DATE  
**December 2, 2009**4. SPONSOR  
**Division of Cancer Treatment and Diagnosis, National Cancer Institute**5. REPORTER=S NAME, TITLE, AND INSTITUTION  
**Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics  
3, IDB, CTEP, DCTD, NCI**6. PHONE NUMBER  
**301-496-1196**7. FAX NUMBER  
**301-402-0428**8. PROTOCOL NUMBER (AE #)  
**E1505 (AE # 1184694)**9. PATIENT IDENTIFICATION  
**15500**10. AGE  
**63**11. SEX  
**Female**

## 12. DESCRIPTION OF ADVERSE EVENT

**The patient was a 63-year-old female with non-small cell lung cancer who died suddenly while on a phase 3 study utilizing the investigational agent bevacizumab in combination with vinorelbine and cisplatin. She began her first course of treatment on October 14, 2009, and received her last dose of bevacizumab, cisplatin and vinorelbine on November 11, 2009 (Cycle 2, Day 1). On November 19, 2009 (Cycle 2, Day 9), the patient presented to the clinic to receive her vinorelbine infusion. The laboratory findings revealed an ANC of 500/mm<sup>3</sup> (reference range: 1500-8000/mm<sup>3</sup>). She was, therefore, unable to receive the treatment; the chemotherapy agents were held and the patient was sent home. On November 23, 2009, her son found her dead at her home. There are unknown details related to her death at this time. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.**

13. DOSE, ROUTE, AND SCHEDULE **Cycle = 21 days**  
**Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 (Cycles 1-4);**  
**Bevacizumab 15 mg/kg IV over 30-90 minutes on Day 1 every 3 weeks, for up to 1 year (Cycles 4+)**14. DATES OF TREATMENT **The patient started the investigational therapy on October 14, 2009, and received the last dose of bevacizumab on November 11, 2009 (Cycle 2, Day 1).**15. ACCRUAL AND IND EXPERIENCE **Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 23774. There have been 48 other cases of sudden death reported to the NCI through AdEERS as serious adverse events for bevacizumab.**16. COMMENTS **The following were also administered:**  
**Cycles 1-4: vinorelbine: 30 mg/m<sup>2</sup>/day IVP over 10 minutes on Days 1 and 8; Cisplatin: 75 mg/m<sup>2</sup> IV over 60 minutes on Day 1 (last administered on November 11, 2009 [Cycle 2, Day 1]).****AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).****DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002